Publications

  1. Planque, S. A., Nishiyama, Y., Sonoda, S., Lin, Y., Taguchi, H., Hara, M., Kolodziej, S., Mitsuda, Y., Gonzalez, V., Sait, H. B., Fukuchi, K., Massey, R. J., Friedland, R. P., O’Nuallain, B., Sigurdsson, E. M., and Paul, S. (2015) Specific amyloid beta clearance by a catalytic antibody construct. J Biol Chem 290, 10229-10241. PMCID: PMC4400338.
  2. Paul, S., Planque, S. A., Massey, R.J. Antibody Engineering. In: Encyclopedia of Life Sciences, eLS. John Wiley & Sons Ltd, Chichester. 2015. DOI: 10.1002/9780470015902.a0001278.pub3.
  3. Nishiyama, Y., Planque, S.A., Hanson, C.V., Massey, R.J., and Paul, S. CD4 binding determinant mimicry for HIV vaccine design. Front. Immun. 3:383, 2012. [DOI: 10.3389/fimmu.2012.00383]. (Invited article)
  4. Planque, S.A., Mitsuda, Y., Nishiyama, Y., Karle, S., Boivin, S., Salas, M., Morris, M.K., Hara, M., Liao, G., Massey, R.J., Hanson, C.V., and Paul, S. Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing a HIV vaccine. J Immunol. 189(11):5367-5381, 2012. [DOI: 10.4049/jimmunol.1200981]. Pubmed
  5. Yang, J., Pattanayak, A., Song, M., Kou, J., Taguchi, H., Paul, S., Ponnazhagan, S., Lalonde, R., and Fukuchi, KI. Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer’s disease mouse model. J Mol Neurosci. 2012 Sep 4 (Epub ahead of print). [DOI: 10.1007/s12031-012-9877-3]. Pubmed
  6. Sapparapu, G., Planque, S., Mitsuda, Y., McLean, G., Nishiyama, Y., and Paul, S. Constant domain-regulated antibody catalysis. J Biol Chem. 287(43):36096-36104, 2012. [DOI: 10.1074/jbc.M112.401075]. Pubmed
  7. Paul, S., Planque, S.A., Nishiyama, Y., Hanson, C.V., and Massey, R.J. Nature and nurture of catalytic antibodies. Adv Exp Med Biol. 750:56-75, 2012. [DOI: 10.1007/978-1-4614-3461-0_5]. Pubmed
  8. Brown, E.L., Nishiyama, Y., Dunkle, J.W., Aggarwal, S., Planque, S., Watanabe, K., Csencsits-Smith, K., Bowden, M.G., Kaplan, S.L., and Paul, S. Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection. J Biol Chem. 287(13):9940-9951, 2012. [DOI: 10.1074/jbc.M111.330043]. Pubmed
  9. Nishiyama, Y. and Paul, S. VIPase: antibody light chain hydrolyzing vasoactive intestinal peptide. Handbook of Proteolytic Enzymes. 3rd Edition, Rawlings, N.D. and Salvesen, G., Eds. (Academic Press, London, England). Expected Release Date 2013 Jan 17.
  10. Kou, J., Kim, H., Pattanayak, A., Song, M., Lim, J.E., Taguchi, H., Paul, S., Cirrito, J.R., Ponnazhagan, S., and Fukuchi, K. Anti-amyloid-β single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer’s disease mouse model. J Alzheimers Dis. 27(1):23-38, 2011. Pubmed
  11. Paul, S., Planque, S., Nishiyama, Y., Escobar, M., Barnett, Z., and Massey, R.J. Covalent vaccination and catalytic antibodies: A new way of looking at and dealing with HIV. GMHC “Treatment Issues.” June 2011. Print version published in POZ magazine, June 2011:21-25. GMHC Link
  12. Paul, S. and Planque, S. Antibody Engineering. Encyclopedia of Life Sciences. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. DOI: 10.1002/9780470015902.a0001278.pub2. 2011.
  13. Paul, S. Two-faced catalytic autoantibodies (Commentary). Blood. 117(7):2084-2086, 2011.
  14. Paul, S., Planque, S., Nishiyama, Y., Escobar, M., and Hanson, C. Back to the future: covalent epitope-based HIV vaccine development. Expert Rev Vaccines. 9(9):1027-1043, 2010. Pubmed
  15. Paul, S., Planque, S., and Nishiyama, Y. Immunological origin and functional properties of catalytic autoantibodies to amyloid β peptide. J Clin Immunol. 30 Suppl 1:S43-S49, 2010. Pubmed
  16. Paul, S., Planque, S., and Nishiyama, Y. Beneficial catalytic immunity to abeta peptide. Proceedings of the Fourth Conference of Strategies for Engineered Negligible Senescence (SENS4). September 3-7, 2009. Queens’ College, Cambridge, United Kingdom. Rejuvenation Res. 13(2-3):179-187, 2010. Pubmed
  17. Planque, S., Salas, M., Mitsuda, Y., Sienczyk, M., Escobar, M.A., Mooney, J.P., Morris, M.-K., Nishiyama, Y., Ghosh, D., Kumar, A., Gao, F., Hanson, C.V., and Paul, S. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS. 24(6):875-884, 2010. Erratum in: AIDS. 25(10):1345-1346, 2011. Pubmed
  18. Nishiyama, Y., Planque, S., Mitsuda, Y., Nitti, G., Taguchi, H., Jin, L., Symersky, J., Boivin, S., Sienczyk, M., Salas, M., Hanson, C.V., and Paul, S. Towards effective HIV vaccination:  Induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem. 284:30627-30642, 2009. Pubmed
  19. Sapparapu, G., Planque, S.A., Nishiyama, Y., Foung, S.K., and Paul, S.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain. J Biol Chem. 284:24622-24633, 2009. Pubmed
  20. Paul, S., Planque, S.A., Nishiyama, Y., and Hanson, C.V.  A covalent HIV vaccine: Is there hope for the future? Future Virology (Editorial) 4:7-10, 2009. NIH public access
  21. Taguchi, H., Planque, S., Sapparapu, G., Boivin, S., Hara, M., Nishiyama, Y., and Paul, S. Exceptional amyloid β peptide hydrolyzing activity of non-physiological immunoglobulin variable domain scaffolds. J Biol Chem. 283:36724-36733, 2008. Pubmed
  22. Planque, S., Salas, M., Escobar, M.E., Morris, M.-K., Jena, B., Mitsuda, Y., Sienczyk, M., Nishiyama, Y., Kumar, A., Gao, F., Montefiori, D.C., Hanson, C.V., and Paul, S. Survivors of HIV infection produce potent, broadly neutralizing IgAs directed to the superantigenic region of the gp120 CD4 binding site. XVII International AIDS Conference (AIDS 2008), 3-8 August, 2008, México City, México. Abstract Number THAA0305.
  23. Planque, S., Sienczyk, M., Nishiyama, Y., Salas, M., Sapparapu, G., Mitsuda, Y., Taguchi, H., Boivin, S., Nitti, G., Montefiori, D., Hanson, C.V., and Paul, S. Prospective clinical utility and evolutionary implication of broadly neutralizing antibody fragments to HIV gp120 superantigenic epitope. XVII International AIDS Conference (AIDS 2008), 3-8 August, 2008, México City, México. Abstract Number LBPE1134. Poster presentation
  24. Planque, S., Nishiyama, Y., Taguchi, H., Salas, M., Hanson, C., and Paul, S. Catalytic antibodies to HIV: Physiological role and potential clinical utility. Autoimmun Rev. (Invited Review) 7:473-479, 2008. Pubmed
  25. Taguchi, H., Planque, S., Nishiyama, Y., Szabo, P., Weksler, M.E., Friedland, R.P., and Paul, S. Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease. Autoimmun Rev. 7:391-397, 2008. Pubmed
  26. Planque, S., Escobar, M.A., Smith, K.C., Taguchi, H., Nishiyama, Y., Donnachie, E., Pratt, K.P., and Paul, S. Covalent inactivation of Factor VIII antibodies from hemophilia A patients by an electrophilic FVIII analog. J Biol Chem. 283:11876-11886, 2008. Pubmed
  27. Taguchi, H., Planque, S., Nishiyama, Y., Symersky, J., Boivin, S., Szabo, P., Friedland, R.P., Ramsland, P.A., Edmundson, A.B., Weksler, M.E., and Paul, S. Autoantibody catalyzed hydrolysis of amyloid β peptide. J Biol Chem. 283:4714-4722, 2008. Pubmed
  28. Planque, S., Mitsuda, Y., Taguchi, H., Salas, M., Morris, M.-K., Nishiyama, Y., Kyle, R., Okhuysen, P., Escobar, M., Hunter, R., Sheppard, H.W., Hanson, C., and Paul, S. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Res Hum Retroviruses. 23:1541-1553, 2007. Pubmed
  29. Nishiyama, Y., Planque, S., Mitsuda, Y., Taguchi, H., Jin, L., Boivin, S., Salas, M., Hanson, C., and Paul, S. A binary neutralizing determinant of gp120 defined by nucleophilic monoclonal antibodies. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007). July 22-25, 2007; Sydney, Australia. Abstract# TUPEA042. Poster presentation
  30. Nishiyama, Y., Mitsuda, Y., Taguchi, H., Planque, S., Salas, M., Hanson, C.V., and Paul, S. Towards covalent vaccination: Improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog. J Biol Chem. 282:31250-31256, 2007. Pubmed
  31. Mitsuda, Y., Planque, S., Hara, M., Kyle, R., Taguchi, H., Nishiyama, Y., and Paul, S. Naturally occurring catalytic antibodies: Evidence for preferred development of the catalytic function in IgA class antibodies. Mol Biotechnol. 36:113-122, 2007. Pubmed
  32. Nishiyama, Y., Karle, S., Planque, S., Taguchi, H., and Paul, S. Antibodies to the superantigenic site of HIV-1 gp120: Hydrolytic and binding activities of the light chain subunit. Mol Immunol. 44:2707-2718, 2007. Pubmed
  33. Nishiyama, Y., Karle, S., Mitsuda, Y., Taguchi, H., Planque, S., Salas, M., Hanson, C., and Paul, S. Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies. J Mol Recognit. 19:423-431, 2006. Pubmed
  34. Olopade, C., Yu, J., Abubaker, J., Mensah, E., and Paul, S. Catalytic hydrolysis of VIP in pregnant women with asthma. J Asthma. 43:429-432, 2006. Pubmed
  35. Huang, M.C., Miller A.I., Wengang, W., Kong, Y., Paul, S., and Goetzl, E.J. Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2). J Immunol. 176:6640-6646, 2006. Pubmed
  36. Paul, S., and Planque, S. Antibody engineering. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd: Chichester http://www.els.net/ [DOI: 10.1038/npg.els.0001278], Published online:  January 27, 2006.
  37. Paul, S., Nishiyama, Y., Planque, S., and Taguchi, H. Theory of proteolytic antibody occurrence. Immunol. Lett. 103:8-16, 2006. Pubmed
  38. Hanson, C.V., Nishiyama, Y., and Paul, S. Catalytic antibodies and their applications. Curr Opin Biotechnol. 16:631-636, 2005. Pubmed
  39. Nishiyama, Y., Mitsuda, Y., Taguchi, H., Planque, S., Hara, M., Karle, S., Hanson, C.V., Taizo, U., and Paul, S. Broadly distributed reactivity of proteins coordinated with specific ligand binding activity. J. Mol. Recognit. 18:295-306, 2005. Pubmed
  40. Paul, S., Nishiyama, Y., Planque, S., Karle, S., Taguchi, H., Hanson, C., and Weksler. M.E. Antibodies as Defensive Enzymes. Springer Semin. Immun. 26:485–503, 2005. Pubmed
  41. Paul, S., Karle, S., Planque, S., Taguchi, H., Salas, M., Nishiyama, Y., Handy, B., Hunter, R., Edmundson, A., and Hanson, C.  Naturally occurring proteolytic antibodies: Selective IgM-catalyzed hydrolysis of HIV gp120. J Biol Chem. 279:39611-39619, 2004. Pubmed
  42. Taguchi, H., Keck, Z., Foung, S.K.H., Paul, S. and Nishiyama, Y. Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide. Bioorg. Med. Chem. Lett. 14:4529-4532, 2004. Pubmed
  43. Voice, J., Donnelly, S., Dorsam, G., Dolganov, G., Paul, S. and Goetzl, E.J. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J. Immunol. 172:7289-7296, 2004. Pubmed
  44. Keck, Z., Sung, V.M.H., Perkins, S., Rowe, J., Paul, S., Liang, T.J., Lai, M.M.C. and Foung, S.K.H. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78:  7257–7263, 2004. Pubmed
  45. Le, A., Dasgupta, S., Planque, S., Paul, S. and Thiagarajan, P.  Lupus-derived antiprothrombin autoantibodies from a V gene phage display library are specific for the kringle 2 domain of prothrombin. Biochemistry. 43:4047-4054, 2004. Pubmed
  46. Planque, S., Bangale, Y., Karle, S., Taguchi, H., Poindexter, B., Bick, R., Edmundson, A., Nishiyama, Y. and Paul, S. Ontogeny of proteolytic immunity: IgM serine proteases. J. Biol. Chem. 279:14024-14032, 2004. Pubmed
  47. Nishiyama, Y., Bhatia, G., Bangale, Y., Planque, S., Mitsuda, Y., Taguchi, H., Karle, S., and Paul, S. Towards selective covalent inactivation of pathogenic antibodies: A phosphonate diester analog of vasoactive intestinal peptide that Inactivates catalytic autoantibodies. J. Biol. Chem.  279:7877–7883, 2004. Pubmed
  48. Karle, S., Planque, S., Nishiyama, Y., Taguchi, H., Zhou, Y.-X., Salas, M., Lake, D., Thiagarajan, P., Arnett, F., Hanson, C.V., and Paul, S. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS. 18:329–331, 2004. Pubmed
  49. Rangan, S.K., Liu, R., Brune, D., Planque, S., Paul, S., and Sierks, M.R. Degradation of β-amyloid by Proteolytic Antibody Light Chains. Biochemistry. 42:14328-14334, 2003. Pubmed
  50. Paul, S., Planque, S., Zhou, Y.-X., Taguchi, H., Bhatia, G., Karle, S., Hanson, C., and Nishiyama, Y. Specific HIV gp120 cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem. 278:20429-20435, 2003. Pubmed
  51. Planque, S., Taguchi, H., Burr, G., Bhatia, G., Karle, S., Zhou, Y.-X., Nishiyama, Y., and Paul, S. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen bonding activity. J. Biol. Chem. 278:20436 – 20443, 2003. Pubmed
  52. Bangale, Y., Karle, S., Zhou, Y.-X., Li, L., Kalaga, R., and Paul, S. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J. 17:628-635, 2003. Pubmed
  53. Karle, S., Nishiyama, Y., Zhou, Y.-X., Luo, J., Planque, S., Hanson, C., and Paul, S. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120. Vaccine. 21:1213–1218, 2003. Pubmed
  54. Planque, S., Zhou, Y.-X., Nishiyama, Y., Sinha, M., O’Connor-McCourt, M., Arnett, F. C., and Paul, S. Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus and autoimmune mice. FASEB J. 17:136-143 2003. Pubmed
  55. Voice, J. K., Grinninger, C., Kong, Y., Bangale, Y., Paul, S., and Goetzl, E. J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 170:308-314, 2003. Pubmed
  56. Bangale, Y., Cavill, D., Gordon, T., Planque, S., Taguchi, H., Bhatia, G., Nishiyama, Y., Arnett, F., and Paul, S. Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice. Peptides. 23:2251-2257, 2002. Pubmed
  57. Taguchi, H., Burr, G., Karle, S., Planque, S., Zhou, Y.-X., Paul, S., and Nishiyama, Y. A mechanism-based probe for gp120-hydrolyzing antibodies.  Bioorg. Med. Chem. Lett. 12:3167–3170, 2002. Pubmed
  58. Zhou, Y.-X., Karle, S., Taguchi, H., Planque, S., Nishiyama, Y., and Paul, S. Prospects for immunotherapeutic proteolytic antibodies. J. Immunol. Methods. 269:257-268, 2002. Pubmed
  59. Nishiyama, Y., Taguchi, H., Luo, J., Zhou, Y.-Z., Burr, G., Karle, S., and Paul, S. Covalent reactivity of a phosphonate monophenyl ester with serine proteinases: An overlooked feature of oxyanionic transition state analogs. Arch. Biochim. Biophys. 402:281–288, 2002. Pubmed
  60. Aleksandrova, E. S., Koralevski, F., Titov, M. I., Demin, A.V., Kozyr’, A. V., Kolesnikov, A. V., Tramontano, A., Paul, S., Thomas, D., Gabibov, A. G., Gnuchev, N. V., and Friboulet, A. A structure-activity study of a catalytic antiidiotypic antibody to the human erythrocyte acetylcholinesterase. Bioorg Khim. 28:118-125, 2002. Pubmed
  61. Berisha, H. I., Bratut, M., Bangale, Y., Colasurdo, G., Paul, S., and Said, S. I. New evidence for transmitter role of VIP in the airways: Impaired airway relaxation by a catalytic antibody to VIP. Pulm. Pharmacol. Ther. 15:121-127, 2002. Pubmed
  62. Alexandrova, E. S., Koralewski, F., Titov, M. I., Demin, A. V., Ignatova, A. N., Kozyr, A. V., Kolesnikov, A. V., Tramontano, A., Paul, S., Thomas, D., Gabibov, A. G., and Friboulet, A. Catalysis of esterolytic reactions by the anti-idiotypic antibody against human erythrocyte acetylcholinesterase. Dokl. Biochem. Biophys. 377:75-78, 2001. Pubmed
  63. Paul, S., Tramontano, A., Gololobov, G., Zhou, Y.-X., Taguchi, H., Karle, S., Nishiyama, Y., Planque, S., and George, S. Phosphonate ester probes for proteolytic antibodies. J. Biol. Chem. 276:28314-28320, 2001. Pubmed
  64. Kolesnikov, A. V., Kozyr, A. V., Alexandrova, E. S., Koralewski, F., Demin, A. V., Titov, M. I., Avalle, B., Tramontano, A., Paul, S., Thomas, D., Gabibov, A. G., and Friboulet, A. Enzyme mimicry by the anti-idiotypic antibody approach. Proc. Natl. Acad. Sci. 97:13526-13531, 2000. Pubmed
  65. Thiagarajan, P., Dannenbring, R., Matsuura, K., Tramontano, A., Gololobov, G., and Paul, S. A monoclonal antibody light chain with prothrombinase activity. Biochemistry. 39:6459-6465, 2000. Pubmed
  66. Thiagarajan, P. and Paul, S. Prothrombin cleaving antibody light chains. In: Chemical Immunology: Catalytic Antibodies. (S. Karger AG, Basel, Switzerland) Ed., S. Paul. Vol. 77, pp. 115-129, 2000. Karger
  67. Tramontano, A., Gololobov, G., and Paul, S. Proteolytic antibodies: Origins, selection and induction. In: Chemical Immunology: Catalytic Antibodies. (S. Karger AG, Basel, Switzerland) Ed., S. Paul. Vol. 77, pp. 1-17, 2000. Karger
  68. Paul, S., Ed. Chemical Immunology: Catalytic Antibodies. (S. Karger AG, Basel, Switzerland) Vol. 77, pp. 1-158, 2000. Karger
  69. Paul, S., Tramontano, A., Sarma, U., Thomas, D., and Gabibov, A., (Eds.) Proceedings of the 3rd International Conference on Catalytic and Super Antibodies. Appl. Biochem. Biotechnol. 83:1-318, 2000.
  70. Li, L., Kalaga, R., and Paul, S. Proteolytic components of serum IgG preparations. Clin. Exp. Immunol. 120:261-266, 2000. Pubmed
  71. Gololobov, G., Tramontano, A., and Paul, S. Nucleophilic proteolytic antibodies. Appl. Biochem. Biotech. 83:221-232, 2000. Pubmed
  72. Tramontano, A., Ivanov, B., Gololobov, G., and Paul, S. Inhibition and labeling of enzymes and abzymes by phosphonate esters. Appl. Biochem. Biotech. 83:233-243, 2000. Pubmed
  73. Paul, S., Kalaga, R., Gololobov, G., and Brenneman, D. Natural catalytic immunity is not restricted to autoantigenic substrates: Identification of a human immunodeficiency virus gp120 cleaving antibody light chain. Appl. Biochem. Biotech. 83:71-84, 2000. Pubmed
  74. Paul, S. and Tramontano, A. Antibody Catalysis – A Super Activity. The Immunologist. 7:163-168, 1999.
  75. Gololobov, G., Sun, M., and Paul, S. Innate antibody catalysis. Mol. Immunol. 36:1215-1222, 1999. Pubmed
  76. Paul, S., Ed. Autoimmune Reactions (Humana Press, Totowa, NJ) pp 1 – 438,1998.
  77. Bosilevac, J. M., Gilchrist, C.A., Jankowski, P.E., Paul, S., Rees, A. R., and Hinrichs, S. H. Inhibition of ATF1 and CREB activated transcription by an intracellular single chain Fv fragment. J. Biol. Chem. 273:16874-16879, 1998. Pubmed
  78. Ikezaki, H., Paul, S., Alkan-Onyuksel, H., Patel, M., Gao, X.-P., and Rubinstein, I. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch. Am. J. Physiol. 275:R56-R62, 1998. Pubmed
  79. Paul, S. Autoantibody catalysis: No longer hostage to Occam’s Razor. Ann. New York Acad. Sci. 865:246-254, 1998. Pubmed
  80. Gololobov, G., Noda, Y., Sherman, S., Rubinstein, I., Baranowska-Kortylewicz, J., and Paul, S. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 285:753 – 758, 1998. Pubmed
  81. Kohler, H. and Paul, S. Superantibodies: New players in innate and adaptive immunity. Immunol. Today. 19: 221 – 227, 1998. Pubmed
  82. Paul, S. VIPASE. In: Handbook of proteolytic enzymes, Barrett A, Woessner F, Rawlings N., Eds. (Academic Press, London, England) pp. 533 – 535, 1998.
  83. Paul, S., Friboulet, A., Gabibov, S., and Thomas, D., Eds. Whither Catalytic Antibodies? Proceeding of 2nd International symposium on Catalytic Antibodies and Antibody Engineering. Appl. Biochem. Biotechnol. 75: 1 – 150, 1998.
  84. Paul, S. Protein engineering. In: Molecular Biotechniques. Walker J, Ed. (Humana Press, Totowa, NJ), Chapter 43, pp 547 – 566, 1998.
  85. Paul, S. Relevance of catalytic anti-VIP antibodies to the airway. In: Pro-inflammatory and anti-inflammatory peptides, Lung Biology in Health and Disease Series, Sami Said, Ed. (Marcel Dekker, New York). Chapter 19, pp 459-475, 1997.
  86. Sun, M., Gao, Q.-S., Kirnarskiy, L., Rees, A., and Paul, S. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. J. Mol. Biol. 271:374-385, 1997. Pubmed
  87. Kohler, H., Paul, S., and Marchalonis, J. Multifunctional variable domains. The Immunologist. 5:98-103, 1997.
  88. Paul, S., Li, L., Kalaga, R., O’Dell, J., Dannenbring Jr., R.E., Swindells, S., Hinrichs, S., Caturegli, P., and Rose, N.R. Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease. J. Immunol. 159:1530-1536, 1997. Pubmed
  89. Sun, M. and Paul, S. Altered cleavage site preference of a proteolytic antibody light chain induced by denaturation. FEBS Lett. 407:289-290, 1997. Pubmed
  90. Tyutyulkova, S., Gao, Q.-S., Thompson, A., Rennard, S., and Paul, S. Efficient vasoactive intestinal polypeptide hydrolyzing autoantibody light chains selected by phage display. Biochimica. Biophysica. Acta. 1316:217-223, 1996. Pubmed
  91. Paul, S. Natural catalytic antibodies. Mol. Biotechnol. 5:197-207, 1996. Pubmed
  92. Paul, S. Proteolytic antibodies. Isr. J. Chem. 36:207-214, 1996.
  93. Li, L., Sun, M., Gao, Q.-S., and Paul, S. Low level formation of potent catalytic IgG fragments mediated by disulfide bond instability. Mol. Immunol. 33:593-600, 1996. Pubmed
  94. Suzuki, H., Noda, Y., Gao, X., Séjourné, F., Alkan-Önyuksel, H., Paul, S., and Rubinstein, I. Encapsulation of VIP into liposomes restores vasorelaxant in hypertension in situ. Am. J. Physiol. (Heart Circ Physiol 40) 271:H282-H287, 1996.
  95. Li, L., Paul, S., Tyutyulkova, S., Kazatchkine, M., and Kaveri, S. Catalytic activity of anti-thyroglobulin antibodies. J. Immunol. 154:3328-3332, 1995. Pubmed
  96. Paul, S., Li, L., Kalaga, R., Wilkins-Stevens, P., Stevens, F. J., and Solomon, A. Natural catalytic antibodies: Peptide hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270:15257-15261, 1995. Pubmed
  97. Tyutyulkova, S., Gao, Q.-S., and Paul, S. Selection of human immunoglobulin light chains from a phage display library. Antibody Engineering Protocols. Ed., Paul S. (Methods in Molecular Biology Series, Humana Press, Totowa, NJ) 51:377-394, 1995.
  98. Gao, Q.-S. and Paul, S. Molecular cloning of anti-ground state proteolytic antibody fragments. Antibody Engineering Protocols. Ed., Paul S. (Methods in Molecular Biology Series, Humana Press, Totowa, NJ). 51:281-296, 1995.
  99. Paul, S., ed. Antibody Engineering Protocols. (Methods in Molecular Biology Series, Humana Press, Totowa, NJ).51:1-450, 1995.
  100. Suzuki, H., Noda, Y., Paul, S., Gao, X.-P., and Rubinstein, I. Encapsulation of vasoactive intestinal peptide into liposomes: Effects on vasodilation in vivo. Life Sciences. 57:1451-1457, 1995. Pubmed
  101. Kalaga, R., Li, L., O’Dell, J., and Paul, S. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J. Immunol. 155:2695-2702, 1995. Pubmed
  102. Gao, Q.-S., Sun, M., Rees, A., and Paul, S. Site-directed mutagenesis of proteolytic antibody light chain. J. Mol. Biol. 253:658-664, 1995. Pubmed

Patents

  • Pending, Treatment and diagnosis of transthyretin amyloidosis using catalytic antibodies. (2013) PCT Application PCT/US2014/047409. Sudhir Paul, Yasuhiro Nishiyama, Stephanie Planque.
  • Pending, Immunoglobulins directed to bacterial, viral and endogeneous polypeptides. (2009). ; U.S. Patent Publication US 12/589,440; Sudhir Paul, Stephanie Planque, Yasuhiro Nishiyama, Eric L. Brown, Keri C. Smith, Hiroaki Taguchi.
  • Pending, Binary epitope antibodies and B cell superantigen immune stimulants.  (2007) EPO Patent Publication EP2091973; Sudhir Paul, Yasuhiro Nishiyama, Stephanie Planque.
  • Pending, Catalytic Immunoglobulins and uses therefor. (2006) ; U.S. Application No US 11/988,761; Sudhir Paul, Yasuhiro Nishiyama, Carl V. Hanson, Marc Weksler.
  • Issued, Covalently reactive transition state analogs and methods of use thereof. (2005)  U.S. Patent No. 7,524,663; Sudhir Paul, Yasuhiro Nishiyama.
  • Issued, Covalently reactive transition state analogs and methods of use thereof.  (2005) U.S. Patent No. 6,855,804; Sudhir Paul, Yasuhiro Nishiyama.
  • Issued, Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding. (2005) Expiration date, 08/04/2028; U.S. Patent No 9,006,388; Sudhir Paul, Yasuhiro Nishiyama.
  • Issued, Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses. (2005) Expiration date, 03/23/2018; U.S. Patent No. 6,855,528; Sudhir Paul, Gennady Gololobov, Larry J. Smith.
  • Issued, Lupus antibodies for passive immunotherapy of HIV/AIDS. (2004) Expiration date, 03/29/2026; U.S. Patent No 8,246,957; Sudhir Paul. License information, Covalent Bioscience is the owner.
  • Issued, Proteolytic and covalent antibodies. (2004) Expiration date, 08/04/2028; U.S. Patent No 8,980,646; Sudhir Paul, Yasuhiro Nishiyama.
  • Issued, Compositions and methods for catalyzing hydrolysis of HIV gp120. (2000) Expiration date, 07/19/2016; U.S. Patent No. 6,156,541; Sudhir Paul, Ravishankar Kalaga.
  • Pending, Combined chemotherapy compositions and methods for the treatment of cancer, ischemia-reperfusion injury, and septic shock. (2005) U.S. Patent Publication 20050214295; Sudhir Paul, Gennady Gololobov, Larry J. Smith.
  • Issued, Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses. (2001) U.S. Patent No. 6,235,714; Sudhir Paul, Gennady Gololobov, Larry J. Smith.
  • Issued, Assay methods and kits for diagnosing autoimmune disease. (2000) U.S. Patent No. 6,130,049; Sudhir Paul, Ravishankar Kalaga.
  • Issued, Inhibitors of catalytic antibodies. (2000) U.S. Patent No. 6,048,717; Sudhir Paul, Michael J. Powell, Richard J. Massey.
  • Issued, Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide. (1998) U.S. Patent No. 5,770,570; Sudhir Paul, Yasuko Noda, Israel Rubinstein.
  • Issued, Catalytic antibody components. (1997) U.S. Patent No. 5,658,753; Sudhir Paul, Michael J. Powell, Richard J. Massey, John H. Kenten.
  • Issued, Autoantibodies which enhance the rate of a chemical reaction. (1997) U.S. Patent No. 5,602,015; Sudhir Paul.
  • Issued, Autoantibodies which enhance the rate of a chemical reaction. (1997) U.S. Patent No. 5,599,538; Sudhir Paul, Lan Li, Srini Kaveri.
  • Issued, Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state. (1994) U.S. Patent No. 5,318,897; Sudhir Paul.
  • Issued, Autoantibodies which enhance the rate of a chemical reaction. (1993) U.S. Patent No. 5,236,836; Sudhir Paul.
  • Issued, Catalytic antibody components. (1993) U.S. Patent No. 5,229,272; Sudhir Paul, Michael J. Powell, Richard J. Massey, John H. Kenten.
  • Issued, Inhibitors of catalytic antibodies. (1993) U.S. Patent No. 5,194,585; Sudhir Paul, Michael J. Powell, Richard J. Massey.